Anaphylaxis is an acute, life-threatening systemic allergic reaction with a lifetime prevalence of 0.05% to 2.0% in developed countries. [1] [2] [3] In human subjects it is largely accepted that anaphylaxis can be triggered by histamine and other mediators released in response to antigen cross-linking of IgE bound to its high-affinity receptor, FcεRI, on mast cells (MCs). [1] [2] [3] However, IgG might also contribute to anaphylaxis in some patients, especially those treated with infused drugs, such as therapeutic mAbs. 4, 5 Several mouse models of anaphylaxis have been developed and used to assess the contributions of IgE and IgG antibodies and the roles of various effector cells and mediators. The analysis of passive local anaphylaxis or passive systemic anaphylaxis (PSA) models has allowed identification of 2 major pathways of anaphylaxis in mice: a ''classical'' pathway consisting of IgE, FcεRI, MCs, and histamine [6] [7] [8] and an ''alternative'' pathway consisting of IgG, FcgRIII and/or FcgRIV, 5,9-11 plateletactivating factor (PAF), 12, 13 and, depending on the exact model used, macrophages, 5,14 basophils, 5, 13 and/or neutrophils. 5, 11, 15 Active systemic anaphylaxis (ASA) models, which are arguably more reflective of the clinical situation, have generated more conflicting results. Some ASA models critically depend on IgE, FcεRI, and MCs, [16] [17] [18] [19] whereas some others can develop, at least with respect to the features analyzed, in IgE , and/or MC-deficient mice. 9, 13, 20 Depending on the mouse strain and ASA model used, basophils have been shown to either contribute to the systemic response 13, 19 or play little to no significant role. 17, 21 Similarly, depletion of monocytes/ macrophages or antibody-mediated neutrophil depletion reduces anaphylaxis in some but not all ASA models. 11, 17, 19, 21 We hypothesize that such conflicting results in ASA models might reflect, at least in part, the choice of adjuvant used during sensitization because various adjuvants might differentially influence the production of individual antibody isotypes. Moreover, in human subjects with anaphylactic reactivity, sensitization to antigen generally occurs in the absence of an artificial adjuvant. Therefore we developed an ''adjuvant-free'' mouse model of ASA and assessed the contributions of components of the classical and alternative pathways of anaphylaxis in this model.
METHODS Mice
C57BL/6J (wild-type [WT]) mice were purchased from Jackson Laboratories (Bar Harbor, Me) or Charles River (Lyon, France). FcgRIII /J mice backcrossed to C57BL/6 for 12 generations) were purchased from Jackson Laboratories. FcRg 2/2 mice (B6.129P2 Fcer1g tm1Rav mice backcrossed to C57BL/6 for 12 generations) were from Taconic (New York, NY). C57BL/6-Kit W-sh/W-sh mice were originally provided by Peter Besmer (Memorial Sloan-Kettering Cancer Center, New York, NY); we then backcrossed these mice to C57BL/6J mice for more than 11 generations. 22 FcεRI 2/2 mice 7 (FcεRI a chain-deficient mice backcrossed to C57BL/6 for more than 8 generations and kindly provided by Jean-Pierre Kinet, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Mass), mast cell protease (Mcpt8) DTR mice (backcrossed to C57BL/6 for at least 10 generations), 23 and carboxypeptidase A3 (Cpa3)-Cre; Mcl-1 fl/fl mice (backcrossed to C57BL/6 for at least 9 generations) 24 were bred and maintained at the Stanford University Research Animal Facility. Age-matched male mice were used in all experiments. Except as otherwise noted, we used littermate controls in all experiments. All animal care and experimentation was conducted in compliance with the guidelines of the National Institutes of Health and specific approval of the Institutional Animal Care and Use Committee of Stanford University and the Animal Ethics Committee CETEA (Institut Pasteur, Paris, France) registered under #C2EA-89.
Ovalbumin-induced adjuvant-free model of active anaphylaxis
Six-to 8-week-old mice were sensitized intraperitoneally with 10 mg of endotoxin-free ovalbumin (OVA; Endograde OVA; BioVendor, Asheville, NC; <0.01 EU endotoxin per injection) in 100 mL of PBS once a week for 6 weeks. Two weeks after the last intraperitoneal sensitization, mice were challenged intraperitoneally with 500 mg of OVA. Rectal measurements of body temperature were performed immediately before (time 0) and at different time points for up to 2 hours after challenge. Mice were killed at various time points after challenge (as indicated) for assessment of inflammatory cell numbers in the peritoneal cavity and histology.
Other methods
See the Methods section in this article's Online Repository at www.jacionline.org for the methods for flow cytometry; peritoneal lavage; differential cell counts; depletion of basophils, monocytes/macrophages, and neutrophils; blockade of FcgRIV; histologic analysis; measurement of serum OVA-specific IgG 1 and IgG 2c antibodies; IgE-mediated PSA; ASA with adjuvant; treatment with an H 1 -antihistamine or a PAF receptor antagonist; quantification of histamine and platelet-activating factor acetylhydrolase (PAF-AH); and generation and adoptive transfer of bone marrow-derived cultured mast cells (BMCMCs).
Statistical analyses
Results represent means 6 SEMs or means 1 SEMs, with values for individual mice represented for quantifications of histamine, PAF-AH, and leukocytes. We used an unpaired Student t test (body temperature) or an unpaired Mann-Whitney U test (all other data) to assess the significance of differences between 2 sets of data. P values of less than .05 are considered statistically significant.
RESULTS

Development of an adjuvant-free model of ASA in C57BL/6 mice
We developed an adjuvant-free mouse model of ASA consisting of intraperitoneal sensitization with endotoxin-free OVA once a week for 6 weeks and intraperitoneal challenge with OVA 2 weeks after the last sensitization (Fig 1, A) . OVA-sensitized C57BL/6 mice had hypothermia after OVA challenge that was maximal at 30 minutes and decreased thereafter (Fig 1, B) . Sensitized and challenged mice also had a late-phase inflammatory response with increased numbers of total cells, eosinophils, macrophages, and lymphocytes in the peritoneal cavity, with the highest numbers of leukocytes on day 3 after challenge (Fig 1, C-H) . Consistent with the increase in eosinophil numbers, we detected significant amounts of IL-5 in the plasma of 3 of 5 OVA-sensitized mice 18 (but not 72) hours after challenge, whereas levels of IL-4, IL-6, IL-10, TNF-a, and IFN-g were all less than the detection limit of standard ELISAs at both time points (data not shown).
OVA-induced hypothermia and inflammation depend on the high-affinity IgE receptor FcεRI, the IgG receptor FcgRIII, and their common activating subunit FcRg OVA sensitization induced a significant increase in OVA-specific IgG 1 and IgG 2c antibody levels in C57BL/6 mice (see Fig E1, A and B, in this article's Online Repository at www.jacionline.org). We did not detect significant levels of OVA-specific IgE in sera by using a standard ELISA (data not shown). However, we observed degranulation of peritoneal cell-derived mast cells (PCMCs) incubated in vitro with sera from OVA-sensitized mice, followed by stimulation with OVA A, Experimental outline. B, Changes in body temperature after challenge with OVA in OVA-sensitized (OVA/OVA) or PBS-treated (PBS/OVA) mice. C-H, Numbers of leukocytes in peritoneal lavage fluid at the indicated time points. Data are pooled from 2 or 3 independent experiments (n 5 6-10 per group). *P < .05, **P < .01, or ***P < .001.
(see Fig E1, C and D) . Such degranulation was not observed with PCMCs incubated with sera from PBS-treated mice or with sera from OVA-sensitized mice, which had been preincubated with anti-IgE antibodies (see Fig E1, C and D) , demonstrating the presence of functional OVA-specific IgE in the sera of sensitized mice.
We then assessed responses of C57BL/6 mice lacking the IgG receptor FcgRIII, the high-affinity IgE receptor FcεRI, or their common activating subunit FcRg. OVA-induced hypothermia was abolished in FcRg 2/2 and FcgRIII 2/2 mice and partially reduced in FcεRI 2/2 mice compared with that seen in WT mice (Fig 2, A) . Antibody-mediated blockade of FcgRIV had no effect , FcgRIII 2/2 , and FcRg 2/2 mice (Fig 2, A) or WT mice treated with an anti-FcgRIV antibody or an isotype control (Fig 2, B) . C-H, Numbers of leukocytes in peritoneal lavage fluid 3 days after challenge. Data are pooled from 2 (Isotype and a-FcgRIV, n 5 7 per group) or 3 (all other groups, n 5 9-15 per group) independent experiments. *P < .05, **P < .01, or ***P < .001. #P < .05, ##P < .01, or ###P < .001.
on immediate hypothermia (Fig 2, B) . WT, FcεRI 2/2 , and FcgRIII 2/2 mice had similar levels of intraperitoneal leukocytes at baseline (except for a small increase in macrophages and lymphocytes in FcgRIII 2/2 mice, see Fig E2 in this article's Online Repository at www.jacionline.org). However, we observed decreased numbers of total cells, macrophages, eosinophils, and lymphocytes in the peritoneal cavities of FcεRI 2/2 and FcgRIII 2/2 mice compared with WT mice 3 days after challenge (Fig 2, C-G) . These numbers were further decreased in mice lacking FcRg (Fig 2, C-G) . Antibody-mediated blockade of FcgRIV induced only a moderate decrease of peritoneal leukocyte numbers at day 3, with reduced numbers of total cells and eosinophils compared with those seen in mice treated with an isotype control antibody (Fig 2, C-G) .
Monocyte/macrophage depletion with clodronate liposomes decreases immediate hypothermia and enhances late-phase intraperitoneal inflammation
We injected OVA-sensitized mice with clodronate liposomes (or PBS liposomes as a control) 24 hours before challenge with OVA to deplete monocytes/macrophages and assess their potential contribution to anaphylaxis through the alternative pathway. Clodronate liposome-treated mice exhibited depletion of circulating CD11b high monocytes at the time of OVA challenge, with no effect on blood Ly6G 1 neutrophils (see Fig E3, A, C, and D, in this article's Online Repository at www.jacionline.org). OVA challenge led to a decrease in CD11b expression in blood monocytes in PBS liposome-treated mice at day 3 (see Fig E3, A) . Consistent with a previous report, 25 we found similar . Data are pooled from 3 independent experiments for all OVA-sensitized groups (total n 5 8-9 per group) and from 1 experiment for nonsensitized control mice (n 5 4-5 per group). *P < .05, **P < .01, or ***P < .001.
percentages of blood monocytes in both PBS liposome-and clodronate liposome-treated mice at day 3 (ie, 4 days after the injection of liposomes; see Fig E3 , A, D, and E). However, F4/80 1 macrophages were depleted in the spleens of clodronate liposome-treated mice at this time point, with no effect on neutrophils (see Fig E3, B, F, and G) . Confirming the efficiency of depletion, we also found that levels of peritoneal macrophages were reduced by 73% in clodronate liposome-treated mice compared with those in control mice at day 3 (Fig 3, E) .
In line with previous reports, 17, 26 treatment with clodronate liposomes reduced features of anaphylaxis in an ASA model using sensitization with OVA together with the adjuvant alum and Bordetella pertussis toxin (see Fig E4, B and C, in this article's Online Repository at www.jacionline.org). Treatment with clodronate liposomes also significantly diminished the hypothermia response in OVA-sensitized and challenged mice in the adjuvant-free ASA model (Fig 3, A) . Clodronate liposometreated mice had lower levels of histamine in plasma 20 minutes after challenge compared with those in PBS liposome-treated mice (Fig 3, B) . Because such a reduction in histamine levels could reflect a toxic effect of the liposomes on MCs, we also assessed responses of mice treated with clodronate or PBS liposomes in an MC-dependent IgE-mediated PSA model. Hypothermia was slightly but not significantly reduced (except at 10 minutes after challenge) in clodronate liposome-treated mice, which suggests that the clodronate liposomes have only modest effects on MC activity in this model (see Fig E3, H) . The activity of PAF-AH (an enzyme that degrades PAF) has been shown to inversely correlate with the severity of anaphylaxis in human subjects. 27 However, we found similar PAF-AH activity in the spleens of mice treated with clodronate or PBS liposomes 20 minutes after challenge (Fig 3, C) . By contrast, clodronate liposome-treated mice displayed significantly higher levels of eosinophils, lymphocytes, and MCs than PBS liposome-treated mice in the peritoneal cavity 3 days after challenge (Fig 3, F-I ). Levels of blood neutrophils were also higher in such clodronate liposome-treated, macrophage-depleted mice compared with those in control mice at day 3 (see Fig E3, A and C). However, we also found a small but significant increase in lymphocyte and MC numbers 3 days after OVA challenge in naive mice treated with clodronate liposomes, which could reflect some proinflammatory effects of the clodronate liposomes (Fig 3, D-I ).
Neutrophils are not required for OVA-induced hypothermia and inflammation
We injected OVA-sensitized mice with an anti-Gr-1 antibody (or an isotype control antibody) 40 hours before and 24 hours after challenge with OVA to deplete neutrophils. Such treatment led to complete ablation of circulating neutrophils at the time of challenge (see Fig E5, A and C, in this article's Online Repository at www.jacionline.org), and neutrophils remained absent in the blood and spleens of anti-Gr-1-treated mice 3 days after challenge (see Fig E5, A-C and F). By contrast, treatment with anti-Gr-1 antibodies did not deplete circulating monocytes or spleen macrophages (and the percentages of these cells were even slightly higher than those in mice treated with the isotype control antibody; see Fig E5, A, B, D, E, and G).
In agreement with findings obtained in IgG-mediated PSA or ASA models using adjuvants for the sensitization, 5, 11 we found that anti-Gr-1-treated mice had markedly reduced features of anaphylaxis compared with isotype control-treated mice in an ASA model using sensitization with OVA together with the adjuvants alum and B pertussis toxin (see Fig E4, D and E). By contrast, isotype control-treated mice and anti-Gr-1-treated mice had similar levels of immediate hypothermia after OVA challenge (Fig 4, A) . Both groups also had similar levels of leukocytes in the peritoneal cavity 3 days after challenge. Although eosinophil and lymphocyte numbers were slightly decreased in the anti-Gr-1-treated group compared with those in the isotype control-treated mice, those differences did not reach statistical significance (Fig 4, B-G ). (Fig 5, G) and MC numbers (Fig 5, H and I) in sections of back skin and ear pinna. J-N, Numbers of leukocytes in the peritoneal lavage fluid 3 days after challenge. Data are pooled from 3 independent experiments (total n 5 9-14 per group). *P < .05, **P < .01, or ***P < .001. Crossbones symbol indicates the death of 1 mouse. Scale bars 5 100 mm.
Cpa3-Cre 1 ; Mcl-1 fl/fl mice also had diminished intraperitoneal inflammation, with decreased numbers of total leukocytes, macrophages, eosinophils, and lymphocytes compared with Cpa3-Cre 1 ; Mcl-1 1/1 mice, indicating that MCs, basophils, or both can also contribute importantly to the late-phase leukocyte numbers in this model (Fig 5, J-N) .
Basophils are not required for OVA-induced hypothermia and inflammation
We assessed the potential role of basophils using Mcpt8 DTR mice, which express the diphtheria toxin receptor (DTR) in basophils only and in which basophils can be selectively ablated by injection of diphtheria toxin (DT). 23 We first confirmed that treatment with DT induces ablation of basophils, but not MCs, in OVA-sensitized Mcpt8 DTR mice (Fig 6, B-D) . We ruled out a significant role for basophils in this model by showing that DTmediated depletion of basophils in OVA-sensitized Mcpt8 DTR mice does not affect OVA-induced hypothermia (Fig 6, A) or late-phase intraperitoneal leukocyte numbers (Fig 6, E-I ).
MCs exacerbate OVA-induced hypothermia and inflammation
We used Kit mutant MC-deficient Kit W-sh/W-sh mice to assess further the contributions of MCs in this ''adjuvant-free'' ASA model. Because Kit W-sh/W-sh mice have many KIT-related phenotypic abnormalities in addition to their MC deficiency, [28] [29] [30] [31] [32] [33] we also included a group of Kit W-sh/W-sh mice that had been engrafted with BMCMCs (BMCMCs/Kit W-sh/W-sh mice) both intraperitoneally and intravenously 12 weeks before the first sensitization with OVA.
We found no significant difference in the severity of anaphylaxis between Kit (Fig 7, A) . BMCMCs/Kit W-sh/W-sh mice had significantly more hypothermia than did Kit W-sh/W-sh mice after challenge with OVA, although levels of hypothermia in these mice did not reach those in Kit 1/1 mice (Fig 7, A) . (Fig 6, B) and percentage (Fig 6, C) of blood basophils (CD49b 1 ; IgE 1 ) 2 hours before challenge. D-I, Numbers of leukocytes in peritoneal lavage fluid 3 days after challenge. Data are pooled from 2 independent experiments (total n 5 7-9 per group). **P < .01. Each crossbones symbol indicates the death of 1 mouse.
J ALLERGY CLIN IMMUNOL VOLUME 139, NUMBER 2 WT mice, MC-engrafted Kit W-sh/W-sh mice had similar levels of MCs in the peritoneal cavity and mesenteric windows and even higher numbers of MCs in the spleen. However, these mice had no detectable MCs in the skin, thus eliminating the numerically large population of skin MCs as a potential source of mediators in such mice (Fig 7 and (Fig 7, B-F) . Confirming the role of MCs in this feature of our ASA model, engraftment of Kit W-sh/W-sh mice with BMCMCs restored levels of total peritoneal leukocytes, neutrophils, eosinophils, macrophages, and lymphocytes quantified 3 days after challenge to those observed in Kit 1/1 mice (Fig 7, B-F) . Altogether, these results show that MCs can amplify both the immediate hypothermia and the late-phase inflammatory reaction in Kit W-sh/W-sh mice in this adjuvant-free ASA model. , and Kit W-sh/W-sh mice engrafted with WT BMCMCs. B-G, Numbers of leukocytes in peritoneal lavage fluid 3 days after challenge. Data are pooled from 3 to 5 independent experiments (total n 5 11-25 per group). *P < .05, **P < .01, or ***P < .001 versus the Kit 1/1 group (Fig 7, A) or indicated group (Fig 7, B-G) . #P < .05 or ##P < .01 versus BMCMCs/Kit W-sh/W-sh group (Fig 7, A) . Crossbones symbol indicates the death of 1 mouse.
Histamine and PAF contribute to OVA-induced hypothermia and inflammation
Pretreatment of mice with the PAF receptor antagonist CV-6209 significantly decreased both the immediate hypothermia and numbers of leukocytes in the late-phase inflammatory response (Fig 8) . Pretreatment with the H 1 -antihistamine triprolidine slightly reduced immediate hypothermia and the numbers of leukocytes in the late-phase response (Fig 8) , although differences did not reach statistical significance, except for eosinophil numbers (Fig 8, D) . However, combined treatment with the antihistamine and PAF receptor antagonist almost entirely blocked both the hypothermia and increased numbers of leukocytes observed during inflammatory responses (Fig 8) . By contrast, treatment with triprolidine markedly reduced both the hypothermia and numbers of intraperitoneal leukocytes in mice pretreated with clodronate liposomes, whereas CV-6209 had no significant effects on these features (see Fig E8 in this article's Online Repository at www.jacionline.org). Collectively, these data demonstrate the involvement of both histamine and PAF in this ASA model in WT mice and suggest that monocytes/macrophages represent the main source of PAF in this model.
DISCUSSION
Most ASA models use adjuvants during the sensitization phase, and such methods typically prime the animals to exhibit allergic reactions that require little or no contribution from MCs and IgE. experiments (total n 5 8 per group). *P < .05, **P < .01, or ***P < .001 versus the vehicle group.
J ALLERGY CLIN IMMUNOL VOLUME 139, NUMBER 2 We hypothesized that use of adjuvants might boost the production of certain IgG isotypes, favoring activation of alternative pathways of anaphylaxis, which might mask contributions from the classical IgE-and MC-dependent pathway. Therefore we designed a new adjuvant-free model of ASA and assessed the potential roles of various components of the classical and alternative pathways in that model.
Our sensitization protocol resulted in production of OVA-specific IgG 1 and IgG 2c antibodies (see Figs E1 and E4 ), 2 isotypes that can induce anaphylaxis through FcgRIII, FcgRIV, or both.
5,10,11 Indeed, we found that FcgRIII 2/2 mice had markedly reduced hypothermia and reduced numbers of peritoneal leukocytes compared with WT mice in this model (Fig 2) . We used an anti-FcgRIV blocking antibody to assess the contribution of this receptor and found no role for FcgRIV in the hypothermia response and a relatively minor contribution to numbers of intraperitoneal leukocytes (Fig 2) . Altogether, our results confirm the important involvement of FcgRIII in allergic shock 10, 11, 17, 26, 34 and reveal that this receptor also has an important role in the development of antigen-induced allergic inflammation.
Although we did not detect significant levels of OVA-specific IgE in the sera of most mice by using a classical ELISA (data not shown), we demonstrated the presence of functionally active specific IgE in sera from OVA-sensitized mice using an ex vivo MC activation test (see Figs E1 and E6 ). These levels of antigen-specific IgE were sufficient to contribute to anaphylaxis and allergic inflammation because mice lacking the high-affinity IgE receptor FcεRI displayed significantly diminished hypothermia and numbers of intraperitoneal leukocytes compared with WT mice (Fig 2) .
These results are in agreement with previous findings showing less hypothermia in FcεRI 2/2 or IgE 2/2 mice in models of peanut-induced ASA. 16, 17, 35 However, our results are in sharp contrast with reports showing no evidence for involvement of IgE or FcεRI in models of OVA-induced ASA that use alum as an adjuvant during the sensitization phase. 9, 10, 20 In line with the strong contributions of both FcgRIII and FcεRI in our model, we found that FcRg 2/2 mice, which lack the common activating subunit of Fcε and Fcg receptors, 36 were completely protected from hypothermia and developed even lower numbers of intraperitoneal leukocytes than FcεRI 2/2 or FcgRIII 2/2 mice (Fig 2) .
In mice FcgRIII is expressed on all myeloid cells, 37 whereas FcεRI is mainly expressed on MCs and basophils. 38 Depending on the model used, MCs, basophils, monocytes/macrophages, and/or neutrophils have been reported to contribute to ASA. 11, 13, 14, [16] [17] [18] [19] 21, 26, 35 Several studies using passive or active models of anaphylaxis have reported an important role for monocytes/macrophages in the immediate hypothermia response after antigen challenge. 5, 14, 17, 21, 26, [39] [40] [41] We confirmed these findings in an ASA model by using the adjuvants alum and B pertussis toxin for sensitization (see Fig E4) . Our depletion experiments also demonstrated that monocytes/macrophages contributed to the hypothermia response in our adjuvant-free ASA model (Fig 2) . By contrast, little is known about the function of monocytes/macrophages in the late-phase allergic inflammation after anaphylaxis. We found that mice treated with clodronate liposomes to deplete monocytes/macrophages exhibited significantly increased numbers of intraperitoneal leukocytes (Fig 2) . This raises the possibility that monocytes/ macrophages can contribute to the resolution phase in this ASA model. However, care should be taken in the interpretation of these findings because such increased leukocyte numbers might also reflect, at least in part, proinflammatory effects of the clodronate liposomes. Indeed, we also found slightly increased numbers of intraperitoneal MCs and lymphocytes in nonsensitized mice treated with clodronate liposomes.
The importance of neutrophils and basophils in anaphylaxis is debated. 15 Some reports indicate that antibody-mediated depletion of neutrophils can reduce IgG 2 -mediated PSA 5,11 and ASA 11 in mice, whereas others found no role for neutrophils in the hypothermia reaction after antigen challenge in IgG-mediated PSA 13, 41 or ASA 19,21 models. In the present study we used anti-Gr-1 antibodies to deplete neutrophils. We found that such treatment markedly reduced anaphylaxis in an ASA model by using the adjuvants alum and B pertussis toxin for sensitization (see Fig E4) . By contrast, we found no significant contribution for neutrophils in either the immediate hypothermia reaction or the late-phase accumulation of intraperitoneal leukocytes in the adjuvant-free ASA model (Fig 4) . Similarly, some reports indicate a contribution of basophils to IgG-mediated PSA 5, 13, 34 or ASA, 11, 17, 19 whereas others found no significant role for basophils in anaphylaxis models.
21,41,42
Here we used conditional basophil-deficient Mcpt8 DTR mice 23 and found no roles for basophils in either the immediate hypothermia reaction or the late-phase allergic inflammation in our adjuvant-free ASA model (Fig 6) . It is largely agreed that MCs play important roles in food allergy and anaphylaxis. 14, [43] [44] [45] Although most of the literature on the roles of MCs in experimental anaphylaxis is based on data obtained by using Kit mutant genetically MC-deficient mice, several new models have been developed in which the MC deficiency is not dependent on mutations affecting c-kit structure or expression. 24 (Fig 7) .
These results stand in marked contrast with previous reports 9, 13 and our own data (see Fig E4) showing that anaphylaxis can fully develop after challenge with OVA in MC-deficient mice sensitized with OVA together with the adjuvant alum. One potential explanation for such results is that MCs are particularly potent at promoting allergic reactions at low levels of antibodies and/or that increased levels of antibodies (promoted by the use of adjuvants during the sensitization phase) lead to a greater contribution of alternative pathways that mask or render redundant the role of MCs. Indeed, previous reports show that the contribution of MCs to some ASA models is greater when using low doses of adjuvant, antigen, or both for sensitization and low doses of antigen for challenge. 17, 19 Our results are also in line with previous reports demonstrating that genetically MC-deficient mice exhibit significantly diminished OVA-induced allergic airway inflammation when sensitized without adjuvant [53] [54] [55] [56] but can fully develop airway inflammation when alum is used as an adjuvant during the sensitization phase. 53, 57 Finally, consistent with previous reports, we found that both histamine and PAF contributed to the immediate hypothermia reaction in WT mice.
14,20,31,58-60 These 2 mediators also contributed to the late-phase inflammatory reaction, with a more pronounced effect of PAF (Fig 8) . By contrast, treatment with a PAF receptor antagonist had no effect in clodronate liposome-treated mice, suggesting that monocytes/macrophages represent the major source of PAF in this adjuvant-free ASA model. As expected, we found that plasma histamine levels were markedly reduced in MC-and basophil-deficient Cpa3-Cre 1 ; Mcl-1 fl/fl mice. More surprisingly, however, we also found reduced plasma histamine levels in clodronate liposome-treated mice (although the reduction was not as substantial as that found in Cpa3-Cre
fl/fl mice), suggesting that monocytes/macrophages might also directly or indirectly contribute to histamine release in this model.
In conclusion, we demonstrate here that FcεRI-and FcgRIII-dependent signaling, histamine, and PAF are required for the full development of hypothermia and intraperitoneal leukocyte accumulation in an adjuvant-free model of ASA. In this model both MCs and monocytes/macrophages are critically involved in the immediate hypothermia reaction. In addition, MCs are also required for the full development of intraperitoneal inflammation, as assessed based on numbers of intraperitoneal leukocytes. Thus our data strongly support the hypothesis that MCs and monocytes/macrophages are the main effector cells of anaphylaxis in this setting.
METHODS
Flow cytometry
We used flow cytometry to identify blood basophils (CD49b 
Peritoneal lavage and differential cell counts
To harvest peritoneal cells, 2 mL of ice-cold PBS was injected into the peritoneal cavity 1 to 4 days (3 days for routine experiments) after OVA challenge, and the abdomen was massaged gently for 20 seconds. Fluid containing peritoneal cells was aspirated, and the cells were resuspended in ice-cold PBS. Total cell numbers were measured with a hemocytometer chamber, and cells were cytocentrifuged onto glass slides and stained with May-Gr€ unwald-Giemsa. Differential cell counts on at least 300 cells were obtained by using standard morphologic criteria.
Depletion of basophils, monocytes/macrophages, or neutrophils and blockade of FcgRIV, PAF, and histamine For neutrophil depletion, mice were injected intraperitoneally with 150 mg of an anti-Gr-1 antibody (RB6-8C5; BioXcell) 40 hours before and 24 hours after challenge with OVA.
E1 Control mice were injected with a rat IgG 2b isotype control antibody (LTF-2; BioXcell). The efficiency of neutrophil depletion was assessed by means of flow cytometric analysis of neutrophils in blood samples (Ly6G 1 ; CD11b 1 ) collected by using retro-orbital bleeding 1 hour before and 3 days after OVA challenge, as well as in spleen samples (Ly6G The potential contributions of histamine and PAF in this model were analyzed based on specific inhibition of the actions of these mediators, according to previously described methods, E2 with slight modifications: the H 1 receptor-specific antihistamine triprolidine was solubilized at 1 mg/mL in sterile saline, and 200 mL was injected intraperitoneally into mice 30 minutes before and 1 day after OVA challenge. The PAF receptor antagonist CV-6209 (Santa Cruz Biotechnology, Dallas, Tex) was diluted at 330 mg/mL in saline, and 200 mL was injected intravenously 30 minutes before and 1 day after OVA challenge.
Evaluation of MCs in mesenteric windows
Evaluation of MCs in mesenteric windows was performed, as previously described.
E3,E4 Briefly, 4 to 5 mesenteric windows from approximately the same locations in each mouse were arranged onto slides and fixed for 1 hour in Carnoy solution (3:2:1 vol/vol/vol of ethanol, chloroform, and acetic acid). The preparations were stained with Csaba stain, which contains both safranin (red, identifying ''mature'' MCs) and Alcian blue (blue, identifying ''less mature'' MCs), which bind to MC cytoplasmic granules.
E3,E4
Histologic analysis
Ear skin (ear pinnae), back skin, and spleen specimens were fixed in 10% formalin and embedded in paraffin, and 4-mm sections were stained with 0.1% Toluidine blue for histologic examination and enumeration of MCs. Images were captured with an Olympus BX60 microscope using a Retiga-2000R QImaging camera run by using Image-Pro Plus Version 6.3 software (Media Cybernetics, Rockville, Md).
Measurement of OVA-specific IgG 1 and IgG 2c antibodies
Peripheral blood was collected by mean of retro-orbital bleeding 24 hours before OVA challenge. Serum OVA-specific IgG 1 and IgG 2c antibody levels were measured by means of ELISA. Briefly, 96-well EIA/RIA plates (Costar, Cambridge, Mass) were coated with 2 mg/well of OVA in 50 nmol/L carbonate-bicarbonate buffer (pH 9.6; Sigma-Aldrich, St Louis, Mo) overnight at 48C. Coated plates were blocked with 1% BSA for 2 hours at room temperature. Plates were washed 3 times, and diluted serum samples were incubated overnight at 48C. We diluted samples 1:100,000 for IgG 1 and 1:50 for IgG 2c . Plates were then washed 3 times and incubated with biotinylated anti-mouse IgG 1 (A85-1; BD PharMingen) or biotinylated anti-mouse IgG 2a/c (R19-15; BD PharMingen) for 1 hour at room temperature. Plates were washed 5 times and incubated with streptavidin-horseradish peroxidase (BD PharMingen) for 30 minutes at room temperature. Plates were washed 3 times and incubated with TMB substrate (Sigma), and the reaction was stopped by addition of 2 mol/L H 2 SO 4 . Absorbance was measured at 450 nm. Anti-OVA IgG 1 (4B4E6; Chondrex) and IgG 2a (M12E4D5; Chondrex, Redmond, Wash) were used as standard antibodies. C57BL/6 does not express IgG 2a but does expresses IgG 2c E5 (the R19-15 detection antibody we used in our ELISA recognizes both IgG 2a and IgG 2c E6 ), and therefore we expressed levels of OVA-specific IgG 2c as arbitrary units.
Generation and adoptive transfer of BMCMCs
Female mouse femoral bone marrow cells were cultured in Dulbecco modified Eagle medium supplemented with 10% FCS, penicillin, and streptomycin and 20% WEHI-3 cell-conditioned medium (as a source of IL-3) to generate BMCMCs. Cells were cultured for 6 weeks, with medium changed twice a week until more than 95% were FcεRIa 1 KIT 1 (assessed by using flow cytometry. data not shown). BMCMCs were transferred by means of intraperitoneal plus intravenous injections (2 3 10 6 cells administered intraperitoneally plus 10 7 cells administered intravenously) into male Kit W-sh/W-sh mice at 4 to 6 weeks of age. Sensitization with OVA was initiated 12 weeks after BMCMC transfer.
Generation of PCMCs
To generate PCMCs, E7 peritoneal cells from C57BL/6J mice were maintained in vitro for 4 weeks in medium containing stem cell factor (10 ng/mL; R&D Systems, Minneapolis, Minn) until MCs represented greater than 95% of the total nonadherent cells, as indicated by May-Gr€ unwaldGiemsa staining.
In vitro MC degranulation assay
We assessed the ability of serum samples (collected 24 hours before the challenge) to sensitize PCMCs for activation in response to OVA in vitro as an ex vivo method to quantify the presence and functional activity of OVA-specific IgE. E8 PCMCs were incubated overnight with sera from PBS-treated or OVA-sensitized mice diluted 1:10 in the PCMC complete culture medium (described above). Cells were washed with PBS and stimulated with 10 ng/mL OVA for 30 minutes at 378C. PCMCs were washed and incubated with avidin-fluorescein isothiocyanate (a probe that specifically binds to heparin contained in MC granules) and PI for 10 minutes on ice. The extent of MC degranulation was assessed in live (PI 2 ) cells by measuring the membrane-bound fraction of granules with flow cytometry, as described previously. E9 In some experiments serum samples were incubated with a rat IgG 1 anti-IgE antibody (R35-92; 50 mg/mL; BD PharMingen) or a rat IgG 1 isotype control antibody (R3-34; 50 mg/mL; BD PharMingen) for 30 minutes at 378C before incubation with BMCMCs.
OVA-induced model of active anaphylaxis using alum and B pertussis for sensitization Mice were sensitized intraperitoneally with 100 mg of endotoxin-free OVA (Endograde OVA; BioVendor; <0.01 EU of endotoxin per injection), 300 ng of B pertussis toxin (Sigma), and 1 mg of Aluminum Hydroxide Gel Adjuvant (alum; InvivoGen, San Diego, Calif) in 200 mL of PBS. Three weeks after sensitization, mice were challenged intraperitoneally with 500 mg of OVA. Rectal measurements of body temperature were performed immediately before (time 0) and at different time points for up to 2 hours after challenge.
IgE-mediated PSA
Purified mouse IgE anti-TNP antibodies (clone C38-2; BD PharMingen) were administered intraperitoneally at a dose of 20 mg in 200 mL of PBS, followed by an intraperitoneal challenge with 500 mg of TNP (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) -BSA (Santa Cruz Biotechnology) in PBS 24 hours later. Rectal measurements of body temperature were performed immediately before (time 0) and at different time points for up to 2 hours after challenge. (Fig E1,  A) and OVA-specific IgG 2c (Fig E1, B) in serum samples collected 24 hours before challenge in PBS-treated or OVA-sensitized C57BL/6 mice. A.U, Arbitrary units. C and D, Sera from PBS-treated or OVA-sensitized mice was incubated for 30 minutes with an anti-IgE antibody (to block soluble IgE) or an isotype control antibody, as indicated. Samples were then incubated overnight with PCMCs. PCMCs were washed and stimulated for 30 minutes with OVA. MC degranulation was monitored by means of fluorescence-activated cell sorting analysis with avidin-fluorescein isothiocyanate (Avidin-FITC) to stain membrane-bound exocytosed granules. Representative fluorescence-activated cell sorting profiles ( Fig  E1, C) and percentages of avidin-FITC 1 degranulated cells (Fig E1, D) are shown. FSC, Forward scatter.
Data are pooled from serum samples collected from 2 (PBS group, total n 5 5) or 3 (OVA group, total n 5 10) independent experiments. *P < .05, **P < .01, and ***P < .001 versus the corresponding control group or the indicated group. PBS lipo. Fig E3, A and B, indicate percentages of each cell population. C-G, Percentage of blood neutrophils (Fig E3, C) , CD11b int blood monocytes (Fig E3, D) , CD11b high blood monocytes (Fig E3, E) , spleen neutrophils (Fig E3, F) , and spleen macrophages (Fig E3, G) at the indicated time points. H, IgE-mediated PSA in mice treated with clodronate liposomes (Clodronate lipo.) of PBS liposomes (PBS lipo.). Fluorescence-activated cell sorting profiles in Fig E3, A and B , are representative of 3 and 2 independent experiments, respectively. Data are pooled from 2 (total n 5 6-8 per group; Fig E3, C-E and H) or 3 (total n 5 9 per group; Fig E3, F and G) independent experiments. *P < .05, **P < .01, or ***P < .001 versus the indicated group. indicate percentages of each cell population. C-G, Percentage of blood neutrophils (Fig E5, C) , CD11b int blood monocytes (Fig E5, D) , CD11b high blood monocytes (Fig E5, E) , spleen neutrophils (Fig E5, F) , and spleen macrophages (Fig E5, G) at the indicated time point. Fluorescence-activated cell sorting profiles in Fig E5, A and B , are representative of 3 and 2 independent experiments, respectively. Data are pooled from 2 (total n 5 6 per group; Fig E5, C-E) or 3 (total n 5 8-9 per group; Fig E5, F and G) independent experiments. *P < .05, **P < .01, or ***P < .001 versus indicated group. (Fig E6, A) and OVA-specific IgG 2c (Fig E6, B) Fig E7, A, are representative of at least 3 independent experiments. Data in Fig E7, B-D , are pooled from at least 3 independent experiments (total n 5 8-14 per group). **P < .01 or ***P < .001 versus the indicated group. N.S., Not significant (P > .05). A, OVA-induced hypothermia. B-G, Numbers of leukocytes in the peritoneal lavage fluid 3 days after OVA challenge. Data are pooled from 2 independent experiments (total n 5 6-8 per group). *P < .05, **P < .01, or ***P < .001 versus the vehicle group.
